2 completed, 1 recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow DTX: new trials by email Literature Review of DTX trials Research Report on DTX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-11-18 | 2026-11-13 |
| A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors CAN04 (nadunolimab), mFOLFOX, DTX - Advanced Solid Tumors, Colorectal Cancer | Phase 1 / Phase 2 | Completed | Cantargia AB | 40 | 2021-09-22 | 2023-07-03 |
| Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC Camrelizumab, Cisplatin, Docetaxel - Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 81 | 2021-06-24 | 2025-07-31 |
Squamous Cell Carcinoma of Head and Neck (2) · Biliary Tract Neoplasms (1) · Carcinoma (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Paranasal Sinus Neoplasms (1) · Prostatic Neoplasms (1) · Salivary Gland Neoplasms (1)
Cantargia AB (1) · National Cancer Institute (NCI) (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1)
China (1) · France (1) · Spain (1) · United States (1)
Charalampos Floudas, M.D. (1) · Chenping Zhang, M.D. (1) · Ignacio Garcia-Ribas, MD, PhD (1)